首页> 外文OA文献 >Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
【2h】

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification

机译:免疫组织化学(IHC)和银增强原位杂交(SISH)同时检测HER2蛋白和基因改变可鉴定有无基因扩增的HER2阳性乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

INTRODUCTION HER2 status assessment became a mandatory test assay in breast cancer, giving prognostic and predictive information including eligibility for adjuvant anti-HER2 therapy. Precise and reliable assessment of HER2 status is therefore of utmost importance. In this study we analyzed breast cancer samples by a novel technology for concomitant detection of the HER2 protein and gene copy number. METHODS Tissue microarrays containing 589 invasive breast cancer samples were analyzed with a double immunohistochemistry (IHC) and silver labeled in situ hybridization (SISH) assay simultaneously detecting HER2 protein and gene copy number in the same tumor cells. This bright-field assay was analyzed using scores according to the modified ASCO guidelines and the results were correlated with patient prognosis. RESULTS Overall concordance rate between protein expression and the presence of gene amplification was 98%. Fifty-seven of 60 tumors (95%) with IHC score 3+, 6 of 10 tumors with IHC score 2+ (60%) and only 3 of 519 tumors (0.6%) with IHC score 0/1+ were amplified by SISH. Patients with gene amplification despite IHC score 0/1+ had a tendency for worse overall survival (p = 0.088, reaching nearly statistical significance) compared to IHC score 0/1+ without amplification. In contrast, there was no difference in overall survival in IHC score 3+/2+ tumors with and without gene amplification. CONCLUSIONS The novel double IHC and SISH assay for HER2 is efficient in the identification of breast cancer with discordant HER2 protein and HER2 gene status, especially for the prognostically relevant groups of HER2 protein negative tumors with HER2 amplification and HER2 protein positive tumors without HER2 amplification. Breast cancer without HER2 amplification among IHC score 2+/3+ tumors (10% in our cohort) suggests that other mechanisms than gene amplification contribute to protein overexpression in these cells.
机译:简介HER2状态评估已成为乳腺癌中的一项强制性检测方法,可提供预后和预测性信息,包括是否有辅助抗HER2治疗的资格。因此,准确可靠地评估HER2的状态至关重要。在这项研究中,我们通过一种用于同时检测HER2蛋白和基因拷贝数的新技术分析了乳腺癌样本。方法采用双重免疫组织化学(IHC)和银标记原位杂交(SISH)分析法,对包含589例浸润性乳腺癌样品的组织微阵列进行分析,同时检测同一肿瘤细胞中的HER2蛋白和基因拷贝数。根据修改后的ASCO指南使用评分对这种明视野分析进行分析,结果与患者的预后相关。结果蛋白质表达与基因扩增存在的总体一致性率为98%。 SISH扩增了IHC得分3+的60个肿瘤中的57个(95%),IHC得分0/1 +的10个肿瘤中的6个(60%)和519 IHC得分0/1 +的519个肿瘤中的3个(0.6%) 。尽管IHC得分为0/1 +,但基因扩增的患者与未扩增的IHC得分为0/1 +的患者相比,总体生存率较差(p = 0.088,达到近乎统计学意义)。相反,有和没有基因扩增的IHC评分3 + / 2 +肿瘤的总生存率没有差异。结论HER2的新型IHC和SISH双重检测方法可有效地鉴定具有不一致的HER2蛋白和HER2基因状态的乳腺癌,特别是对于具有HER2扩增和没有HER2扩增的HER2蛋白阴性肿瘤的预后相关组。在IHC评分为2 + / 3 +的肿瘤中,没有HER2扩增的乳腺癌(在我们的队列研究中为10%)表明,基因扩增以外的其他机制也导致了这些细胞中蛋白质的过度表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号